A6476
ABT-418 hydrochloride
powder, ≥98% (HPLC)
Synonym(s):
3-Methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]isoxazole hydrochloride
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C9H14N2O · HCl
CAS Number:
Molecular Weight:
202.68
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
solubility
H2O: soluble 15 mg/mL
originator
Abbott
SMILES string
Cl.CN1CCC[C@H]1c2cc(C)no2
InChI
1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1
InChI key
VOXHERKWAIEJQF-QRPNPIFTSA-N
General description
ABT-418 is an α4β2 agonist of nicotinic receptors.
Application
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer′s disease.
ABT-418 hydrochloride has been used as a nicotinic acetylcholine receptor (nAChR) agonist to test its effect on spatial memory improvement in attention deficit hyperactivity disorder (ADHD) rat model
Biochem/physiol Actions
Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.
Features and Benefits
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J D Brioni et al.
Psychopharmacology, 119(4), 368-375 (1995-06-01)
Previous studies have established that ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. A series of experiments was conducted to
Tianyou Guo et al.
Neuroscience letters, 528(1), 11-15 (2012-09-19)
Impaired learning performance in scholastic settings is a characteristic of attention deficit hyperactivity disorder (ADHD). Our present study compares the effect of a nicotinic acetylcholine receptor (nAChR) agonist, ABT-418, and methylphenidate (MPH) on spatial memory in spontaneously hypertensive rats (SHRs)
J D Brioni et al.
The Journal of pharmacology and experimental therapeutics, 271(1), 353-361 (1994-10-01)
The hydrochloride salt of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418), a potent activator of select subtypes of neuronal nicotinic acetylcholine receptors enhanced retention in memory tests and induced anxiolytic-like effects in mice in the elevated plus maze. In the present studies in rats
Nikolaos Pitsikas
Behavioural brain research, 393, 112778-112778 (2020-06-25)
Several lines of evidence indicate that anesthetic doses of the non-competitive N-methyl-D-aspartate receptor antagonist ketamine disrupt memory functions in rodents. The mechanism by which anesthetic ketamine produces its adverse behavioural effects is not yet clarified. The implication of nicotinic acetylcholine
R Nikolov
Drug news & perspectives, 11(4), 248-255 (2004-12-24)
The 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy focused on new therapeutic approaches for the treatment of Alzheimer 's disease (AD) based on the latest basic science data. The two major pharmacological principles of cholinergic therapy are 1)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service